학술논문
The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma
Document Type
Article
Author
Horwitz, S.; O'Connor, O.A.; Pro, B.; Trümper, L.; Iyer, S.; Advani, R.; Bartlett, N.L.; Christensen, J.H.; Morschhauser, F.; Domingo-Domenech, E.; Rossi, G.; Kim, W.S.; Feldman, T.; Menne, T.; Belada, D.; Illés, Á.; Tobinai, K.; Tsukasaki, K.; Yeh, S.-P.; Shustov, A.; Hüttmann, A.; Savage, K.J.; Yuen, S.; Zinzani, P.L.; Miao, H.; Bunn, V.; Fenton, K.; Fanale, M.; Puhlmann, M.; Illidge, T.
Source
In Annals of Oncology March 2022 33(3):288-298
Subject
Language
ISSN
0923-7534